日本大学医学部附属板橋病院は、東京都板橋区大谷口上町にある医療機関。日本大学医学部の附属病院である。同医学部に隣接しており、特定機能病院の承認を受ける。病院長は高橋悟。略称は日大板橋病院。

During the past decade, Nihon University Itabashi Hospital conducted 15 clinical trials. In the 10-year time frame, 15 clinical trials started and 12 clinical trials were completed, i.e. on average, 80% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 9 clinical trials were completed. i.e. 128.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Nihon University Itabashi Hospital" #1 sponsor was "Pfizer" with 6 trials, followed by "Bayer" with 5 trials sponsored, "Bristol-Myers Squibb" with 3 trials sponsored, "Eli Lilly and Company" with 3 trials sponsored and "Amgen" with 3 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Nihon University Itabashi Hospital" #1 collaborator was "Astellas Pharma Inc" with 1 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator, "Korean Cancer Study Group" with 1 trials as a collaborator, "Medivation LLC, a wholly owned subsidiary of Pfizer Inc." with 1 trials as a collaborator and "Sanofi" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Nihon University Itabashi Hospital" are "Psoriasis" (5 trials), "Anemia" (2 trials), "Gastric Cancer" (2 trials), "Renal Insufficiency, Chronic" (2 trials) and "Asthma" (1 trials). Many other conditions were trialed in "Nihon University Itabashi Hospital" in a lesser frequency.

Most popular intervention types in "Nihon University Itabashi Hospital" are "Drug" (22 trials), "Other" (4 trials), "Biological" (2 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (9 trials), "BMS-986165" (3 trials), "Apixaban" (2 trials), "Apremilast" (2 trials) and "Axitinib (AG-013736)" (2 trials). Other intervention names were less common.

The vast majority of trials in "Nihon University Itabashi Hospital" are 23 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Nihon University Itabashi Hospital". undefined are not yet recruiting, 4 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 16 completed trials in Nihon University Itabashi Hospital, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Nihon University Itabashi Hospital, 0 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 18 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".